2 Information about empagliflozin

Marketing authorisation indication

2.1 Empagliflozin (Jardiance, Boehringer Ingelheim) has a marketing authorisation 'in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.


2.3 The list price of 10 mg or 25 mg empagliflozin is £36.59 per 28‑tablet pack (excluding VAT; BNF online, accessed November 2021). The annual treatment cost is £476.98. Costs may vary in different settings because of negotiated procurement discounts.

  • National Institute for Health and Care Excellence (NICE)